Weight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weekly
- 1PlexusDx
Abstract
BackgroundTirzepatide is conventionally initiated at 2.5 mg weekly and titrated to approved maintenance doses. Evidence describing weight change at injectable starting doses below 2.5 mg/week is limited.
MethodsWe conducted a retrospective, single-organization observational study of adults documented as new GLP-1 starts, with baseline body mass index (BMI) [≥]27 kg/m2, who initiated compounded injectable tirzepatide at a microdose of 1 or 2 mg/week (below the standard 2.5 mg/week starting dose). Source records were reviewed for baseline validity, prior treatment, weight consistency, and treatment exposure. The main descriptive analysis selected the latest eligible measurement per patient within observation windows of 14-35, 36-59, and 60-89 days of adjudicated treatment exposure, excluding observations after escalation above 2 mg/week. All 93 eligible measurements were included in a supporting random-intercept model. Analyses were retrospective and hypothesis-generating; no formal sample-size calculation was performed.
ResultsSixty patients contributed 93 eligible follow-up measurements, of which 84 were selected for patient-window summaries. Mean age was 47.3 years, 81.7% were female, and mean baseline BMI was 33.3 kg/m2. Mean body-weight loss was 2.18% (95% CI 1.61-2.76; n=57) in the 14-35-day window at a median 21 days, 3.58% (95% CI 2.43-4.72; n=19) in the 36-59-day window at a median 48 days, and 6.10% (95% CI 4.60-7.60; n=8) in the 60-89-day window at a median 65.5 days. The adjusted model estimated 2.16 percentage points greater loss per 30 days of treatment exposure (95% CI 1.69-2.63).
ConclusionsWeight loss was observed within the 14-35-, 36-59-, and 60-89-day observation windows among evaluable adults initiating compounded injectable tirzepatide at 1-2 mg/week. These uncontrolled findings are hypothesis-generating; the 36-59- and 60-89-day estimates are particularly limited by sparse follow-up.
Research in contextO_ST_ABSEvidence before this studyC_ST_ABSRandomized trials demonstrate substantial long-term weight reduction with tirzepatide 5-15 mg/week after initiation at 2.5 mg/week. Real-world studies also support effectiveness, but published evidence specifically evaluating tirzepatide initiation below 2.5 mg/week remains sparse. We did not identify a randomized comparison of 1-2 mg/week initiation versus the labeled schedule.
Added value of this studyThis study applies source-record validation and treatment-start adjudication to 93 follow-up weight measurements from 60 documented new starts. It describes weight change during treatment at 1-2 mg/week and distinguishes individual measurements from patient-window summaries.
ImplicationsThe findings support prospective comparative evaluation of lower-dose tirzepatide initiation with standardized weight and adverse-event measurement.
Related
- Clinical outcomes of tirzepatide in a real-world follow-up cohort of patients with type 2 diabetes
- Tirzepatide safety in EudraVigilance: descriptive and disproportionality analysis of preferred terms related to suboptimal treatment outcomes and drug-use-related issues
- Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters
- Body Weight Changes and Exploratory Metabolic Outcomes During Semaglutide and Tirzepatide Treatment: A Real-World Longitudinal Cohort Study from Türkiye
- Values Expressed by Women Veterans Initiating Treatment for Sleep Apnea
BibTeX
@misc{hastings2026weight,
title = {{Weight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weekly}},
author = {J. Hastings and J. Lee},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.15.26363172},
url = {https://www.medrxiv.org/content/10.64898/2026.09.15.26363172v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Weight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weekly
AU - J. Hastings
AU - J. Lee
PY - 2026
DA - 2026/09/15
PB - medRxiv
DO - 10.64898/2026.09.15.26363172
UR - https://www.medrxiv.org/content/10.64898/2026.09.15.26363172v1
AB - BackgroundTirzepatide is conventionally initiated at 2.5 mg weekly and titrated to approved maintenance doses. Evidence describing weight change at injectable starting doses below 2.5 mg/week is limited. MethodsWe conducted a retrospective, single-organization observational study of adults documented as new GLP-1 starts, with baseline body mass index (BMI) [≥]27 kg/m2, who initiated compounded injectable tirzepatide at a microdose of 1 or 2 mg/week (below the standard 2.5 mg/week starting dose). Source records were reviewed for baseline validity, prior treatment, weight consistency, and treatment exposure. The main descriptive analysis selected the latest eligible measurement per patient within observation windows of 14-35, 36-59, and 60-89 days of adjudicated treatment exposure, excluding observations after escalation above 2 mg/week. All 93 eligible measurements were included in a supporting random-intercept model. Analyses were retrospective and hypothesis-generating; no formal sample-size calculation was performed. ResultsSixty patients contributed 93 eligible follow-up measurements, of which 84 were selected for patient-window summaries. Mean age was 47.3 years, 81.7% were female, and mean baseline BMI was 33.3 kg/m2. Mean body-weight loss was 2.18% (95% CI 1.61-2.76; n=57) in the 14-35-day window at a median 21 days, 3.58% (95% CI 2.43-4.72; n=19) in the 36-59-day window at a median 48 days, and 6.10% (95% CI 4.60-7.60; n=8) in the 60-89-day window at a median 65.5 days. The adjusted model estimated 2.16 percentage points greater loss per 30 days of treatment exposure (95% CI 1.69-2.63). ConclusionsWeight loss was observed within the 14-35-, 36-59-, and 60-89-day observation windows among evaluable adults initiating compounded injectable tirzepatide at 1-2 mg/week. These uncontrolled findings are hypothesis-generating; the 36-59- and 60-89-day estimates are particularly limited by sparse follow-up. Research in contextO_ST_ABSEvidence before this studyC_ST_ABSRandomized trials demonstrate substantial long-term weight reduction with tirzepatide 5-15 mg/week after initiation at 2.5 mg/week. Real-world studies also support effectiveness, but published evidence specifically evaluating tirzepatide initiation below 2.5 mg/week remains sparse. We did not identify a randomized comparison of 1-2 mg/week initiation versus the labeled schedule. Added value of this studyThis study applies source-record validation and treatment-start adjudication to 93 follow-up weight measurements from 60 documented new starts. It describes weight change during treatment at 1-2 mg/week and distinguishes individual measurements from patient-window summaries. ImplicationsThe findings support prospective comparative evaluation of lower-dose tirzepatide initiation with standardized weight and adverse-event measurement.
ER -